Vimpat

Vimpat is a brand name of lacosamide, approved by the FDA in the following formulation(s):

VIMPAT (lacosamide - solution; intravenous)

• 
  Manufacturer: UCB INC
  
  Approval date: October 28, 2008
  
  Strength(s): 200MG/20ML (10MG/ML) ^[RLD]

VIMPAT (lacosamide - solution; oral)

• 
  Manufacturer: UCB INC
  
  Approval date: April 20, 2010
  
  Strength(s): 10MG/ML ^[RLD]

VIMPAT (lacosamide - tablet; oral)

• 
  Manufacturer: UCB INC
  
  Approval date: October 28, 2008
  
  Strength(s): 100MG, 150MG, 200MG ^[RLD], 50MG
  

Has a generic version of Vimpat been approved?

No. There is currently no therapeutically equivalent version of Vimpat available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Vimpat. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Amino acid derivative anticonvulsant
  Patent 5,654,301
  Issued: August 5, 1997
  Inventor(s): Kohn; Harold L. & Watson; Darrell
  Assignee(s): Research Corporation Technologies, Inc.
  The present invention relates to compounds of the formula ##STR1##
  
  Patent expiration dates:
  
  
  • August 5, 2014
    
    ✓ 
    Patent use: METHOD OF TREATING, AS ADJUNCTIVE THERAPY, PARTIAL-ONSET SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS AND OLDER
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  
  
  • August 5, 2014
    
    ✓ 
    Patent use: METHOD OF TREATING, AS ADJUNCTIVE THERAPY, PARTIAL-ONSET SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS AND OLDER WHEN ORAL TREATMENT IS TEMPORARILY NOT FEASIBLE
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  Anticonvulsant enantiomeric amino acid derivatives
  Patent RE38551
  Issued: July 6, 2004
  Inventor(s): Harold; Kohn
  Assignee(s): Research Corporation Technologies, Inc.
  The present invention is directed to a compound in the R configuration about the asymmetric carbon in the following formula: pharmaceutical compositions containing same and the use thereof in treating CNS disorders in animals.
  
  Patent expiration dates:
  
  
  • March 17, 2017
    
    ✓ 
    Patent use: METHOD OF TREATING, AS ADJUNCTIVE THERAPY, PARTIAL-ONSET SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS AND OLDER
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  
  
  • March 17, 2017
    
    ✓ 
    Patent use: METHOD OF TREATING, AS ADJUNCTIVE THERAPY, PARTIAL-ONSET SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS AND OLDER WHEN ORAL TREATMENT IS TEMPORARILY NOT FEASIBLE
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • October 28, 2013 - NEW CHEMICAL ENTITY
  
  

See also...

• Vimpat Consumer Information (Drugs.com)
• Vimpat Consumer Information (Wolters Kluwer)
• Vimpat Tablets Consumer Information (Wolters Kluwer)
• Vimpat Consumer Information (Cerner Multum)
• Vimpat Advanced Consumer Information (Micromedex)
• Vimpat Intravenous Advanced Consumer Information (Micromedex)
• Vimpat AHFS DI Monographs (ASHP)
• Lacosamide Consumer Information (Wolters Kluwer)
• Lacosamide Tablets Consumer Information (Wolters Kluwer)
• Lacosamide Consumer Information (Cerner Multum)
• Lacosamide Advanced Consumer Information (Micromedex)
• Lacosamide Intravenous Advanced Consumer Information (Micromedex)
• Lacosamide AHFS DI Monographs (ASHP)